HLA-C: The Potential Drug Target and Biomarker (G3107)

Target Name: HLA-C

NCBI ID: G3107

HLA-C: The Potential Drug Target and Biomarker

HLA-C is a human leukocyte antigen (HLA) that is expressed in the major histocompatibility complex (MHC) and is involved in the immune response. HLA-C is a key molecule in the immune system and plays a crucial role in the regulation of T cell development and function. HLA-C has also been identified as a potential drug target and biomarker for various diseases, including cancer, autoimmune disorders, and inflammatory diseases.

Disease-Related HLA-C expression

HLA-C is expressed in various tissues and cells of the body and is involved in the immune response. HLA-C is highly co-expressed in many diseases, including cancer, autoimmune disorders, and inflammatory diseases. For example, HLA-C is highly co-expressed in breast cancer and has been used as a biomarker for disease progression and response to chemotherapy.

In addition to its involvement in cancer, HLA-C has also been linked to the development and progression of autoimmune disorders, such as rheumatoid arthritis, lupus, and multiple sclerosis. HLA-C has also been shown to be involved in the regulation of immune cell function and has been implicated in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

HLA-C as a drug target

HLA-C has been identified as a potential drug target due to its involvement in the immune response and its role in the development of various diseases. One of the main reasons for HLA-C's potential as a drug target is its involvement in the regulation of T cell development and function. HLA-C is a key molecule in the regulation of T cell receptor (TCR) diversity and function, and has been shown to play a role in the development of autoimmune disorders.

HLA-C has also been shown to be involved in the regulation of T cell proliferation and differentiation, and has been linked to the development of various types of cancer. For example, studies have shown that HLA-C is highly co-expressed in various types of cancer and that it is involved in the development and progression of these diseases.

In addition to its involvement in T cell regulation, HLA-C has also been shown to be involved in the regulation of immune cell function and has been implicated in the development of neurodegenerative diseases. For example, studies have shown that HLA-C is involved in the regulation of dendritic cell function and has been linked to the development of Alzheimer's disease.

HLA-C as a biomarker

HLA-C has also been used as a biomarker for various diseases, including cancer, autoimmune disorders, and inflammatory diseases. For example, HLA-C has been used as a biomarker for breast cancer and has been shown to be involved in the development and progression of this disease.

HLA-C has also been used as a biomarker for autoimmune disorders, such as rheumatoid arthritis and lupus. Studies have shown that HLA-C is highly co-expressed in these disorders and that it is involved in the development and progression of these diseases.

In addition to its use as a biomarker, HLA-C has also been shown to be involved in the regulation of immune cell function and has been implicated in

Protein Name: Major Histocompatibility Complex, Class I, C

Functions: Antigen-presenting major histocompatibility complex class I (MHCI) molecule with an important role in reproduction and antiviral immunity (PubMed:20972337, PubMed:24091323, PubMed:20439706, PubMed:11172028, PubMed:20104487, PubMed:28649982, PubMed:29312307). In complex with B2M/beta 2 microglobulin displays a restricted repertoire of self and viral peptides and acts as a dominant ligand for inhibitory and activating killer immunoglobulin receptors (KIRs) expressed on NK cells (PubMed:16141329). In an allogeneic setting, such as during pregnancy, mediates interaction of extravillous trophoblasts with KIR on uterine NK cells and regulate trophoblast invasion necessary for placentation and overall fetal growth (PubMed:20972337, PubMed:24091323). During viral infection, may present viral peptides with low affinity for KIRs, impeding KIR-mediated inhibition through peptide antagonism and favoring lysis of infected cells (PubMed:20439706). Presents a restricted repertoire of viral peptides on antigen-presenting cells for recognition by alpha-beta T cell receptor (TCR) on HLA-C-restricted CD8-positive T cells, guiding antigen-specific T cell immune response to eliminate infected cells, particularly in chronic viral infection settings such as HIV-1 or CMV infection (PubMed:11172028, PubMed:20104487, PubMed:28649982). Both the peptide and the MHC molecule are recognized by TCR, the peptide is responsible for the fine specificity of antigen recognition and MHC residues account for the MHC restriction of T cells (By similarity). Typically presents intracellular peptide antigens of 9 amino acids that arise from cytosolic proteolysis via proteasome. Can bind different peptides containing allele-specific binding motifs, which are mainly defined by anchor residues at position 2 and 9. Preferentially displays peptides having a restricted repertoire of hydrophobic or aromatic amino acids (Phe, Ile, Leu, Met, Val and Tyr) at the C-terminal anchor (PubMed:8265661, PubMed:25311805)

More Common Targets